Bigtincan Holdings Limited Share Price

Equities

BTH

AU000000BTH6

Biotechnology & Medical Research

Market Closed - Australian S.E. 07:10:23 29/05/2024 BST 5-day change 1st Jan Change
0.145 AUD 0.00% Intraday chart for Bigtincan Holdings Limited -3.33% -27.50%

Financials

Sales 2024 * 124M 81.65M 6.43B Sales 2025 * 122M 80.82M 6.36B Capitalization 89.36M 59.06M 4.65B
Net income 2024 * -9M -5.95M -468M Net income 2025 * 5M 3.3M 260M EV / Sales 2024 * 0.59 x
Net cash position 2024 * 16.59M 10.97M 864M Net cash position 2025 * 14.08M 9.31M 733M EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-
P/E ratio 2025 *
16.1 x
Employees 495
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 week-3.33%
Current month-3.33%
1 month-3.33%
3 months-34.09%
6 months-14.71%
Current year-27.50%
More quotes
1 week
0.15
Extreme 0.145
0.16
1 month
0.14
Extreme 0.14
0.17
Current year
0.14
Extreme 0.14
0.26
1 year
0.14
Extreme 0.135
0.56
3 years
0.14
Extreme 0.135
1.53
5 years
0.14
Extreme 0.135
1.60
10 years
0.14
Extreme 0.135
1.60
More quotes
Managers TitleAgeSince
Founder - 31/12/10
President - 31/12/11
Chief Operating Officer - 31/10/14
Members of the board TitleAgeSince
Director/Board Member - 05/10/21
Director/Board Member - 27/09/16
Founder - 31/12/10
More insiders
Date Price Change Volume
29/05/24 0.145 0.00% 669,842
28/05/24 0.145 -3.33% 547,015
27/05/24 0.15 -6.25% 1,147,923
24/05/24 0.16 +3.23% 390,567
23/05/24 0.155 +3.33% 1,281,299

Delayed Quote Australian S.E., May 29, 2024 at 07:10 am

More quotes
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.145 AUD
Average target price
0.39 AUD
Spread / Average Target
+168.97%
Consensus

Annual profits - Rate of surprise